Retina Institute of California Medical Group, a California Medical Par
Retina Institute of California Medical Group, a California Medical Par was paid $64.25M by Medicaid between Jan 2018 and Dec 2024, across 77 billing codes. Its largest line is 67028, Intravitreal injection of a pharmacologic agent — 27% of everything it billed.
33Billing provider infoRETINA INSTITUTE OF CALIFORNIA MEDICAL GROUP, A CALIFORNIA MEDICAL PAR
PASADENA, CA 91105
PASADENA, CA 91105
33aNPI1760541569assigned 12/07/2006
33bProvider typeOptometrist
28Total paid$64.25M
24GClaims1,263,273
24DCodes billed77
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Optometrist providers in California
Rank by total paid#1 of 1,899
Median peer was paid$23K
This provider vs. median2,847×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 78,018 | $4.25M | |
| 2019 | 127,225 | $7.29M | |
| 2020 | 137,179 | $8.48M | |
| 2021 | 177,183 | $9.47M | |
| 2022 | 210,884 | $10.44M | |
| 2023 | 272,205 | $12.17M | |
| 2024incomplete | 260,579 | $12.16M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 67028 | Intravitreal injection of a pharmacologic agent | 27% | 94,749 | 76,902 | $17.39M |
| 92134 | 8.6% | 178,023 | 150,954 | $5.52M | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 7.5% | 9,090 | 8,670 | $4.83M |
| J2778 | Injection, ranibizumab, 0.1 mg | 7.0% | 16,142 | 12,988 | $4.52M |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 6.8% | 182,087 | 174,931 | $4.35M |
| J9035 | Injection, bevacizumab, 10 mg | 5.4% | 62,220 | 50,408 | $3.46M |
| 68761 | 5.3% | 44,405 | 25,467 | $3.39M | |
| 92235 | 5.1% | 57,007 | 56,704 | $3.27M | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | 3.9% | 100,912 | 93,194 | $2.52M |
| 92250 | 3.4% | 57,253 | 56,606 | $2.16M | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | 2.5% | 54,529 | 54,434 | $1.59M |
| 67228 | 2.3% | 6,963 | 5,788 | $1.45M |
65 more codes
| 99204 | Doctor's office visit, new patient (more involved) | 1.7% | 17,658 | $1.12M |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.7% | 34,125 | $1.08M |
| 67210 | 1.6% | 3,660 | $1.00M | |
| 99213 | Doctor's office visit, returning patient (routine) | 1.3% | 35,369 | $834K |
| V2020 | Frames, purchases | 1.1% | 54,244 | $722K |
| 92133 | <1% | 25,070 | $519K | |
| 92136 | <1% | 12,103 | $436K | |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | <1% | 2,010 | $430K |
| 92340 | Fitting of spectacles, except for aphakia; monofocal | <1% | 36,560 | $425K |
| 92083 | <1% | 19,577 | $403K | |
| 92015 | Determination of refractive state | <1% | 79,195 | $385K |
| 68810 | <1% | 3,363 | $366K | |
| 66821 | <1% | 3,161 | $308K | |
| J0178 | Injection, aflibercept, 1 mg | <1% | 797 | $280K |
| 92020 | <1% | 18,264 | $242K | |
| 92341 | <1% | 11,936 | $209K | |
| 67031 | <1% | 1,634 | $143K | |
| 68020 | <1% | 1,110 | $82K | |
| 92002 | <1% | 3,347 | $70K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 927 | $70K |
| 92201 | <1% | 5,013 | $64K | |
| 76514 | <1% | 6,268 | $54K | |
| 92242 | <1% | 698 | $50K | |
| 92226 | <1% | 2,021 | $47K | |
| 76512 | <1% | 1,502 | $44K | |
| 67800 | <1% | 731 | $42K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 1,970 | $40K |
| 67820 | <1% | 1,550 | $33K | |
| 65205 | <1% | 828 | $32K | |
| 92060 | <1% | 1,131 | $31K | |
| 65778 | <1% | 1,095 | $29K | |
| 67700 | <1% | 572 | $28K | |
| 92025 | <1% | 1,503 | $26K | |
| 99205 | Prolong outpt/office vis | <1% | 266 | $22K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,163 | $19K |
| J2777 | Injection, faricimab-svoa, 0.1 mg | <1% | 32 | $15K |
| 67108 | <1% | 14 | $14K | |
| 66982 | <1% | 26 | $13K | |
| 66761 | <1% | 72 | $12K | |
| 92225 | <1% | 410 | $11K | |
| 65855 | <1% | 110 | $8K | |
| 92202 | <1% | 859 | $7K | |
| 67938 | <1% | 52 | $6K | |
| 2022F | <1% | 2,343 | $6K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 212 | $6K |
| 92227 | <1% | 799 | $2K | |
| 67145 | <1% | 12 | $1K | |
| 99024 | <1% | 243 | $802.17 | |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 1,809 | $651.74 |
| V2103 | Spherocylinder, single vision, plano to plus or minus 4.00d sphere, .12 to 2.00d cylinder, per lens | <1% | 53 | $435.13 |
| V2025 | Deluxe frame | <1% | 14 | $388.08 |
| V2100 | Sphere, single vision, plano to plus or minus 4.00, per lens | <1% | 17 | $219.60 |
| 76519 | <1% | 15 | $153.08 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 16 | $118.10 |
| 0517F | <1% | 60 | $113.60 | |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | <1% | 737 | $106.40 |
| 92285 | <1% | 15 | $47.39 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | <1% | 56 | $38.43 |
| 2023F | 0% | 328 | $0.00 | |
| 3072F | 0% | 600 | $0.00 | |
| G8755 | Most recent diastolic blood pressure >= 90 mmhg | 0% | 30 | $0.00 |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 103 | $0.00 |
| G8752 | Most recent systolic blood pressure < 140 mmhg | 0% | 81 | $0.00 |
| 5010F | 0% | 319 | $0.00 | |
| G8753 | Most recent systolic blood pressure >= 140 mmhg | 0% | 35 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHANG, TOM (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Trilogy Eye Medical Group INC | Pasadena, CA | $2.52M |
| Orange Asc, LLC | Santa Ana, CA | $1.08M |
| San Gabriel Ambulatory Surgery Center, LP | Arcadia, CA | $841K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.